These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 385922)

  • 21. Post-marketing surveillance.
    Lasagna L
    Triangle; 1980; 19(3-4):107-11. PubMed ID: 7013216
    [No Abstract]   [Full Text] [Related]  

  • 22. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychopharmacology. The medication merry-go-round.
    Brown K
    Science; 2003 Mar; 299(5613):1646-9. PubMed ID: 12637713
    [No Abstract]   [Full Text] [Related]  

  • 24. Balancing risks versus benefits in drug therapy decisions.
    Lasagna L
    Clin Ther; 1998; 20 Suppl C():C72-9. PubMed ID: 9915092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Kennedy version of the Drug Regulation Reform Act.
    Greenberg RB
    Am J Hosp Pharm; 1979 Sep; 36(9):1230-4. PubMed ID: 386790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How the US drug safety system should be changed.
    Strom BL
    JAMA; 2006 May; 295(17):2072-5. PubMed ID: 16670415
    [No Abstract]   [Full Text] [Related]  

  • 27. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence behind FDA alerts for drugs with adverse cardiovascular effects: implications for clinical practice.
    Rackham DM; C Herink M; Stevens IG; Cardoza NM; Singh H
    Pharmacotherapy; 2014; 34(4):358-72. PubMed ID: 24347043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cochlear implants: overview of safety and effectiveness. The FDA evaluation.
    Yin L; Segerson DA
    Otolaryngol Clin North Am; 1986 May; 19(2):423-33. PubMed ID: 3520445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory aspects of investigational new drugs.
    Arbit HM
    Am J Hosp Pharm; 1978 Jan; 35(1):81-5. PubMed ID: 341700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs: the tortuous road to approval.
    Visscher MB
    Science; 1967 Apr; 156(3773):313. PubMed ID: 4887262
    [No Abstract]   [Full Text] [Related]  

  • 34. Postmarketing surveillance for oncology drugs.
    Viale PH; Moore S
    Clin J Oncol Nurs; 2008 Dec; 12(6):877-86. PubMed ID: 19064381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reporting drug side effects: signals and noise.
    Avorn J
    JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853
    [No Abstract]   [Full Text] [Related]  

  • 37. Review of the processes for FDA oversight of drugs, medical devices, and combination products.
    Sweet BV; Schwemm AK; Parsons DM
    J Manag Care Pharm; 2011; 17(1):40-50. PubMed ID: 21204589
    [No Abstract]   [Full Text] [Related]  

  • 38. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of the Drug Regulation Reform Act of 1978 on clinical research, drug availability, and the public health.
    Temple RJ
    Ann N Y Acad Sci; 1981; 368():175-85. PubMed ID: 7020537
    [No Abstract]   [Full Text] [Related]  

  • 40. Post-marketing studies of drug efficacy: why?
    Strom BL; Melmon KL; Miettinen OS
    Am J Med; 1985 Mar; 78(3):475-80. PubMed ID: 3976706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.